Search filters

List of works by Karim Belhadj

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

scientific article

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

scientific article published on 15 May 2019

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

scientific article published on 19 December 2019

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

scientific article published on 22 February 2020

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

scientific article published on 11 December 2015

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

scientific article published on April 2017

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

scientific article published on 03 October 2018

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

scientific article

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

scientific article

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

scientific article

Paulina is supported by:

About Paulina

Help